Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients.
In an attempt to determine the safety, tolerance, and prophylactic antiviral activity of high doses of recombinant DNA leucocyte interferon A a double-blind parallel-group study was started in 16 renal transplant recipients. All 16 patients had early rejection episodes. In all 8 interferon-treated patients and 1 placebo-treated patient this rejection, which was of the acute vascular humoral type, was steroid resistant. 3 interferon-treated patients also had transient nephrotic syndrome.
D000208:Acute Disease; D002986:Clinical Trials as Topic; D003587:Cytomegalovirus; D004274:DNA, Recombinant; D004311:Double-Blind Method; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007370:Interferon Type I / Q000009:adverse effects*; D016030:Kidney Transplantation; D007970:Leukopenia / Q000209:etiology; D009404:Nephrotic Syndrome / Q000209:etiology; D011183:Postoperative Complications / Q000517:prevention & control; D011897:Random Allocation; D014657:Vasculitis / Q000209:etiology
D004274:DNA, Recombinant; D007370:Interferon Type I